Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentCompleted18 and overPharmaceutical / Industry20050181

Trial Description


The purpose of this study is to evaluate the treatment effect of panitumumab plus FOLFIRI compared to FOLFIRI alone as second line therapy for metastatic colorectal cancer.

Eligibility Criteria

Inclusion Criteria:

  • Man or woman at least 18 years old
  • Diagnosis of metastatic colorectal cancer
  • One and only one chemotherapy regimen for mCRC consisting of first-line 5-FU -based chemotherapy
  • Radiologically documented disease progression per modified RECIST criteria during treatment or within 6 months of last dose of first-line chemotherapy
  • At least 1 uni-dimensionally measurable lesion of at least 20 mm per modified RECIST
  • ECOG status of 0, 1, or 2
  • Paraffin-embedded tumor tissue from the primary tumor or metastasis available for central analyses
  • Adequate hematologic, renal, and hepatic functions
  • Negative pregnancy test within 72 hours of enrollment
  • Other protocol-specified criteria may apply

Exclusion Criteria:

  • History of or known presence of CNS metastases
  • History of another primary cancer within 5 years of randomization
  • Prior irinotecan therapy
  • Prior anti-EGFr antibody therapy or treatment with small molecule EGFr inhibitors
  • Any investigational agent or therapy within 30 days before randomization
  • Known allergy or hypersensitivity to irinotecan, 5-FU or leucovorin
  • History of interstitial lung disease or evidence of interstitial lung disease on baseline chest CT scan
  • Active inflammatory bowel disease or other bowel disease causing chronic diarrhea
  • Known positive tests for HIV, HCV, acute or chronic active HBV
  • Major surgery within 28 days of randomization or minor surgical procedure within 14 days of randomization
  • Pregnant or breast-feeding
  • Man or woman of child-bearing potential not consenting to use adequate contraceptive methods or abstinence during the course of the study and for 6 months after last study drug administration (women) or 1 month after last study drug administration (men)
  • Other protocol-specified criteria may apply

Trial Contact Information

Trial Lead Organizations/Sponsors

Amgen, Incorporated

    MD, Study Director

    Link to the current record.
    NLM Identifier NCT00339183 processed this data on April 09, 2015

    Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to